The United Kingdom and the United States have established a key trade agreement that will preserve zero import taxes on British pharmaceutical shipments being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the public health system. This commitment secures that tariffs on these key products will stay at zero for a timeframe of 36 months.
This agreement comes after earlier threats to significantly raise tariffs on patented drug products, with figures mentioned as high as double the cost.
"This agreement between the United Kingdom strengthens the global environment for cutting-edge drugs and brings long-overdue fairness to American-British medicine commerce," a statement said.
Commercial Importance
Medicines are one of the Britain's biggest exports to the United States, which is clearly the biggest market for large British pharmaceutical firms.
Export figures reveal that in the year prior to last September, the UK shipped medicines worth billions to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee protects jobs, boosts investment and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister stated.
Detailed NHS Changes
The deal includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates topped 20%.
Industry Background
The pact comes amid a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American patients were charged several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been halted or cancelled, while major funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
